Siegfried DINAMIQS webinar
Manufacturing viral vectors
for in-vivo applications
Advancing delivery systems for the next generation of therapies
In-vivo gene delivery is one of the most dynamic frontiers in cell and gene therapy. From ophthalmology to neurology, systemic administration of viral vectors is redefining what’s possible. However, it brings unique challenges in vector design, development, and GMP manufacturing—especially for programs scaling toward IND.
What you'll learn:
Design considerations for in-vivo vectors
Learn how to optimize viral vector platforms—especially lentiviral and AAV—for in-vivo delivery, including tissue targeting, immunogenicity, and payload capacity.
Overcoming manufacturing challenges
Understand key hurdles in scale-up and purity for in-vivo applications, and how to address them through upstream and downstream innovation.
Navigating regulatory and analytical expectations
Gain insight into how regulatory expectations shape analytical design, release criteria, and critical quality attributes for vectors used in systemic or organ-specific gene delivery.
Register to join
In this webinar, Dr. Eduard Ayuso, CTO of Siegfried DINAMIQS, will share critical considerations from the lab bench to the manufacturing suite, including how to push the limits of vector purity, potency, and scalability. You’ll hear about design strategies for in-vivo success, real-world lessons from program development, and how to future-proof your vector platform for regulatory and clinical translation.
Why you shouldn't miss this session:
Get expert guidance from a scientific leader
Dr. Ayuso brings over 20 years of deep expertise in viral vector development and in-vivo delivery strategies across academic and industry settings.
Turn scientific complexity into strategic clarity
Walk away with practical frameworks to evaluate, refine, and scale your in-vivo vector platforms for clinical and commercial readiness.
Stay ahead of the curve in a rapidly evolving field
As gene delivery technologies advance, staying updated on vector biology, safety considerations, and analytical design is critical. This session distills current trends and future directions into an accessible format for R&D and translational teams.
Meet the speaker
Eduard Ayuso
Dr. Eduard Ayuso, CTO Siegfried DINAMIQS, is an expert in the field of gene therapy using viral vector platforms. With more than 50 scientific publications and over two decades of academic and industry consulting experience, Eduard has made significant contributions to the field of in vivo gene transfer in small and large animal models of diseases, as well as viral vector development and analytics. He has served as Head of Innovative Vectorology at the French National Institute of Health and Medical Research (INSERM), and as the Scientific Director of the Translational Vector Core unit at the University of Nantes. Eduard earned his PhD in Biochemistry and Molecular Biology and his DVM from the Autonomous University of Barcelona.